Healthcare provider profile · identity verified

Kyle Lee, D.O.

Family Practice · LOS ANGELES, CA · NPI 1326290842

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	508	179
Amlodipine Besylate	Amlodipine Besylate	246	99
Lisinopril	Lisinopril	183	70
Levothyroxine Sodium	Levothyroxine Sodium	164	54
Losartan Potassium	Losartan Potassium	144	59
Metformin Hcl	Metformin Hcl	140	49
Simvastatin	Simvastatin	126	50
Rosuvastatin Calcium	Rosuvastatin Calcium	118	48
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	116	44
Trazodone Hcl	Trazodone Hcl	113	30
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	105	36
Atenolol	Atenolol	104	39
Albuterol Sulfate Hfa	Albuterol Sulfate	103	57
Omeprazole	Omeprazole	93	39
Terazosin Hcl	Terazosin Hcl	93	29
Metoprolol Tartrate	Metoprolol Tartrate	91	34
Tamsulosin Hcl	Tamsulosin Hcl	87	31
Metformin Hcl Er	Metformin Hcl	85	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	65	21
Alendronate Sodium	Alendronate Sodium	63	24
Finasteride	Finasteride	63	24
Glipizide	Glipizide	63	23
Tramadol Hcl	Tramadol Hcl	58	21
Pradaxa	Dabigatran Etexilate Mesylate	57	18
Pantoprazole Sodium	Pantoprazole Sodium	56	20
Allopurinol	Allopurinol	55	24
Terbinafine Hcl	Terbinafine Hcl	52	29
Wixela Inhub	Fluticasone Propion/Salmeterol	50	21
Ibuprofen	Ibuprofen	49	25
Furosemide	Furosemide	48	18
Carvedilol	Carvedilol	40	12
Lovastatin	Lovastatin	40	13
Fenofibrate	Fenofibrate	39	14
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	39	14
Bisoprolol Fumarate	Bisoprolol Fumarate	38	13
Hydrochlorothiazide	Hydrochlorothiazide	38	20
Potassium Chloride	Potassium Chloride	38	14
Triamcinolone Acetonide	Triamcinolone Acetonide	38	26
Meloxicam	Meloxicam	35	16
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	32	12
Hydralazine Hcl	Hydralazine Hcl	31	13
Montelukast Sodium	Montelukast Sodium	31	15
Spironolactone	Spironolactone	31	13
Prednisone	Prednisone	29	25
Gabapentin	Gabapentin	26	suppressed
Sertraline Hcl	Sertraline Hcl	26	suppressed
Warfarin Sodium	Warfarin Sodium	24	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	22	suppressed
Cephalexin	Cephalexin	21	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	20	20
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Fentanyl	Fentanyl	20	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	19	19
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Alvesco	Ciclesonide	17	13
Ezetimibe	Ezetimibe	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Eliquis	Apixaban	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	15	suppressed
Azithromycin	Azithromycin	15	14
Propranolol Hcl	Propranolol Hcl	15	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	15	suppressed
Fluticasone Propionate	Fluticasone Propionate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Metoprolol Succinate	Metoprolol Succinate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Humulin N	Insulin Nph Human Isophane	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Primidone	Primidone	12	suppressed
Risedronate Sodium	Risedronate Sodium	12	suppressed
Risperidone	Risperidone	12	suppressed
Topiramate	Topiramate	12	suppressed
Baclofen	Baclofen	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error